A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.44.10.2900-2902.2000PMID 10991885PMCID PMC90176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?

  1998cited by this paper
• Renal effects of amphotericin B lipid complex.

  1998cited by this paper
• Antifungal agents. Part I. Amphotericin B preparations and flucytosine.

  1998cited by this paper
• Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

  1998cited by this paper
• Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies

  1997cited by this paper
• Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats

  1997cited by this paper
• Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

  1997cited by this paper
• Amphotericin B and its delivery by liposomal and lipid formulations

  1993cited by this paper
• Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B

  1993cited by this paper
• Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities

  1993cited by this paper
• Complexes of Amphotericin B and Cholesteryl Sulfate

  1993cited by this paper
• Liposomal and Lipid Formulations of Amphotericin B

  1992cited by this paper
• Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.

  1991cited by this paper
• Amphotericin B Nephrotoxicity

  1990cited by this paper
• Amphotericin B: 30 years of clinical experience.

  1990cited by this paper
• Unusual lipid structures selectively reduce the toxicity of amphotericin B.

  1988cited by this paper
• Amphotericin B nephrotoxicity.

  1988cited by this paper

• Current Antifungals and the Developing Pipeline.

  2025cites this paper
• Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications

  2025cites this paper
• Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications

  2022cites this paper
• Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics

  2021cites this paper
• [Liposomal amphotericin B: Clinical pharmacology, pharmacokinetics and pharmacodynamics].

  2021cites this paper
• Antifungals in Clinical Use and the Pipeline.

  2021cites this paper
• Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion.

  2021cites this paper
• Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

  2020cites this paper
• In Vitro and In Vivo Study of Amphotericin B Formulation with Quaternized Bioreducible Lipidoids.

  2020cites this paper
• Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

  2019cites this paper
• Clinically relevant in vitro dissolution/release testing for parenteral formulations

  2019cites this paper
• Nanocarrier-based systems for targeted and site specific therapeutic delivery.

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of antifungal drugs in children

  2018cites this paper
• SPIN: rapid synthesis, purification, and concentration of small drug-loaded liposomes

  2018cites this paper
• Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions‐ case example Amphotericin B

  2018cites this paper
• Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

  2017influential citation
• Safe and Effective Delivery of Amphotericin B: A Survey of Patents.

  2017cites this paper
• Assessment of multi-wavelength pulse photometry for non-invasive dose estimation of circulating drugs and nanoparticles

  2016cites this paper
• Drug Targeting in Nanomedicine and Nanopharmacy: A Systems Approach

  2016cites this paper
• Hybrid Nanoparticles as Drug Carriers for Controlled Chemotherapy of Cancer.

  2016cites this paper
• Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.

  2013cites this paper
• Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.

  2013cites this paper
• Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?

  2012cites this paper
• Amphotericin B Lipid Complex

  2012cites this paper
• Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections

  2012cites this paper
• EUCAST technical note on Amphotericin B.

  2011cites this paper
• Simultaneous determination of purity and potency of amphotericin B by HPLC

  2011cites this paper
• Antifungal treatment of small animal veterinary patients.

  2010cites this paper
• Intrapulmonary Disposition of Amphotericin B After Aerosolized Delivery of Amphotericin B Lipid Complex (Abelcet; ABLC) in Lung Transplant Recipients

  2010cites this paper
• Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.

  2009cites this paper
• Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

  2009cites this paper
• Preparation, Relative Toxicity, Chemotherapeutic Activity, and Pharmacokinetics of Liposomal SJA-95: A New Polyene Macrolide Antibiotic

  2008cites this paper
• Amphotericin B formulations and drug targeting.

  2008cites this paper
• Preparation, relative toxicity, chemotherapeutic activity, and pharmacokinetics of liposomal SJA-95: a new polyene macrolide antibiotic.

  2008cites this paper
• Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis

  2007cites this paper
• Clinical pharmacokinetics of systemically administered antimycotics.

  2007cites this paper
• [Pharmacokinetic of antifungal drugs in order to optimize their administration].

  2006cites this paper
• Eficiência terapêutica das formulações lipídicas de anfotericina B

  2006cites this paper
• Pharmacocinétique des antifongiques en fonction du terrain

  2006cites this paper
• Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.

  2006cites this paper
• Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates

  2005influential citation
• Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature

  2004cites this paper
• Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration.

  2004influential citation
• ADVANCED DRUG DELIVERY

  2004cites this paper
• Development of liposomal polyene antibiotics: an historical perspective.

  2003cites this paper
• New agents for the treatment of systemic fungal infections – current status

  2002cites this paper
• Relationship of Pharmacokinetically-Calculated Volumes of Distribution to the Physiologic Distribution of Liposomal Drugs in Tissues: Implications for the Characterization of Liposomal Formulations

  2001influential citation